Regulatory2026-06-01

Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)

Intellia Therapeutics Inc.NTLA
Indication
Hereditary angioedema (HAE)
Stage
phase4
Event
Submission